A retrospective analysis of the clinical characteristics of vaccinated COVID-19 patients admitted to a tertiary Hospital, Northern Iran

Fatemeh  Fathabadi; Meysam  Hasannejad-Bibalan; Hadi  Sedigh Ebrahim-Saraie; Tofigh  Yaghubi Kalurazi

doi:10.61882/jcbior.5.3.298

Authors

Fatemeh Fathabadi Razi Clinical Research Development Unit, Razi Hospital, Guilan University of Medical Sciences, Rasht, Iran
Meysam Hasannejad-Bibalan Department of Microbiology, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran
Hadi Sedigh Ebrahim-Saraie Department of Microbiology, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran
Tofigh Yaghubi Kalurazi Razi Clinical Research Development Unit, Razi Hospital, Guilan University of Medical Sciences, Rasht, Iran https://orcid.org/0000-0002-6042-2331

DOI:

https://doi.org/10.61882/jcbior.5.3.298

Keywords:

COVID-19, SARS‑CoV‑2, Vaccination, Clinical symptoms, Outcomes research

Abstract

Coronavirus disease 2019 (COVID-19) vaccines have played a critical role in reducing the severity and complications of severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) infection. While various vaccine types have been administered globally, the clinical manifestations of COVID-19 among vaccinated individuals may differ based on the number of doses received. This study aimed to evaluate and compare the initial clinical characteristics of vaccinated COVID-19 patients. This retrospective descriptive-analytical study was conducted on 594 adult patients with confirmed COVID-19 who had received at least one dose of a COVID-19 vaccine. Patients were admitted to Razi Hospital in Rasht, Iran, between June 6, 2021 and March 21, 2022. Medical records were reviewed to collect demographic data, vaccination history, and clinical symptoms at admission. Patients were categorized into three groups: one dose, two doses, and three doses (booster). Clinical symptoms and oxygen saturation levels were compared across these groups. Among 594 patients, 30% had received one dose, 55.1% two doses, and 15% three doses of a COVID-19 vaccine. Fever, cough, myalgia, respiratory distress, and anosmia showed significant differences across the groups. The mean oxygen saturation was highest in the two-dose group. No significant differences were observed in comorbidities among the groups. The number of vaccine doses received was associated with differences in several clinical symptoms and oxygen saturation levels among hospitalized patients. These findings suggest a possible dose-related trend in clinical presentation among vaccinated individuals.

References

1. Krammer F. SARS-CoV-2 vaccines in development. Nature. 2020;586(7830):516-527. DOI: 10.1038/s41586-020-2798-3 PMID: 32967006

2. Thanh Le T, Andreadakis Z, Kumar A, Gómez Román R, Tollefsen S, Saville M, et al. The COVID-19 vaccine development landscape. Nat Rev Drug Discov. 2020;19(5):305-306. DOI: 10.1038/d41573-020-00073-5 PMID: 32273591

3. Modes ME, Directo MP, Melgar M, Johnson LR, Yang H, Chaudhary P, et al. Clinical Characteristics and Outcomes Among Adults Hospitalized with Laboratory-Confirmed SARS-CoV-2 Infection During Periods of B.1.617.2 (Delta) and B.1.1.529 (Omicron) Variant Predominance - One Hospital, California, July 15-September 23, 2021, and December 21, 2021-January 27, 2022. MMWR Morb Mortal Wkly Rep. 2022;71(6):217-223. DOI: 10.15585/mmwr.mm7106e2 PMID: 35143466

4. Clinical characteristics and outcomes of COVID-19 patients with a history of cardiovascular disease. Journal of Current Biomedical Reports. 2022;3(1):36-42. DOI: 10.52547/jcbior.3.1.36

5. Halaji M, Heiat M, Faraji N, Ranjbar R. Epidemiology of COVID-19: An updated review. J Res Med Sci. 2021;26:82.

DOI: 10.4103/jrms.JRMS_506_20 PMID: 34759999

6. Lechien JR, Chiesa-Estomba CM, Place S, Van Laethem Y, Cabaraux P, Mat Q, et al. Clinical and epidemiological characteristics of 1420 European patients with mild-to-moderate coronavirus disease 2019. J Intern Med. 2020;288(3):335-344. DOI: 10.1111/joim.13089 PMID: 32352202

7. Pan Y, Li X, Yang G, Fan J, Tang Y, Zhao J, et al. Serological immunochromatographic approach in diagnosis with SARS-CoV-2 infected COVID-19 patients. J Infect. 2020;81(1):e28-e32. DOI: 10.1016/j.jinf.2020.03.051 PMID: 32283141

8. Zeinali T, Faraji N, Joukar F, Khan Mirzaei M, Kafshdar Jalali H, Shenagari M, et al. Gut bacteria, bacteriophages, and probiotics: Tripartite mutualism to quench the SARS-CoV2 storm. Microb Pathog. 2022;170:105704. DOI: 10.1016/j.micpath.2022.105704 PMID: 35948266

9. Marincu I, Citu C, Bratosin F, Bogdan I, Timircan M, Gurban CV, et al. Clinical Characteristics and Outcomes of COVID-19 Hospitalized Patients: A Comparison between Complete mRNA Vaccination Profile and Natural Immunity. J Pers Med. 2022;12(2):259. DOI: 10.3390/jpm12020259 PMID: 35207747

10. Iwasaki A, Omer SB. Why and How Vaccines Work. Cell. 2020;183(2):290-295. DOI: 10.1016/j.cell.2020.09.040

PMID: 33064982

11. Yu J, Tostanoski LH, Peter L, Mercado NB, McMahan K, Mahrokhian SH, et al. DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science. 2020;369(6505):806-811. DOI: 10.1126/science.abc6284 PMID: 32434945

12. Spiekermann GM, Finn PW, Ward ES, Dumont J, Dickinson BL, Blumberg RS, et al. Receptor-mediated immunoglobulin G transport across mucosal barriers in adult life: functional expression of FcRn in the mammalian lung. J Exp Med. 2002;196(3):303-10. DOI: 10.1084/jem.20020400

PMID: 12163559

13. Reynolds HY. Immunoglobulin G and its function in the human respiratory tract. Mayo Clin Proc. 1988;63(2):161-74.

DOI: 10.1016/s0025-6196(12)64949-0 PMID: 3276975

14. Pakkanen SH, Kantele JM, Moldoveanu Z, Hedges S, Häkkinen M, Mestecky J, et al. Expression of homing receptors on IgA1 and IgA2 plasmablasts in blood reflects differential distribution of IgA1 and IgA2 in various body fluids. Clin Vaccine Immunol. 2010;17(3):393-401. DOI: 10.1128/CVI.00475-09

PMID: 20089794

15. Harvey WT, Carabelli AM, Jackson B, Gupta RK, Thomson EC, Harrison EM, et al. SARS-CoV-2 variants, spike mutations and immune escape. Nat Rev Microbiol. 2021;19(7):409-424.

DOI: 10.1038/s41579-021-00573-0 PMID: 34075212

16. Shrotri M, Navaratnam AMD, Nguyen V, Byrne T, Geismar C, Fragaszy E, et al. Spike-antibody waning after second dose of BNT162b2 or ChAdOx1. Lancet. 2021;398(10298):385-387. DOI: 10.1016/S0140-6736(21)01642-1 PMID: 34274038

17. Thomas SJ, Moreira ED Jr, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. N Engl J Med. 2021;385(19):1761-1773. DOI: 10.1056/NEJMoa2110345 PMID: 34525277

18. The Lancet Infectious Diseases. COVID-19 vaccine equity and booster doses. Lancet Infect Dis. 2021;21(9):1193.

DOI: 10.1016/S1473-3099(21)00486-2 PMID: 34391506

19. Shekhar R, Garg I, Pal S, Kottewar S, Sheikh AB. COVID-19 Vaccine Booster: To Boost or Not to Boost. Infect Dis Rep. 2021;13(4):924-929. DOI: 10.3390/idr13040084

PMID: 34842753

20. Hany M, Torensma B. Incidence and presentation of COVID-19 in the vaccinated and unvaccinated patients undergoing bariatric surgery. Obes Pillars. 2022;2:100019.

DOI: 10.1016/j.obpill.2022.100019 PMID: 37990713

21. Antonelli M, Penfold RS, Merino J, Sudre CH, Molteni E, Berry S, et al. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study. Lancet Infect Dis. 2022;22(1):43-55. DOI: 10.1016/S1473-3099(21)00460-6 PMID: 34480857

22. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603-2615. DOI: 10.1056/NEJMoa2034577 PMID: 33301246

23. Menni C, Klaser K, May A, Polidori L, Capdevila J, Louca P, et al. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. Lancet Infect Dis. 2021;21(7):939-949. DOI: 10.1016/S1473-3099(21)00224-3 PMID: 33930320

24. Pritchard E, Matthews PC, Stoesser N, Eyre DW, Gethings O, Vihta KD, et al. Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom. Nat Med. 2021;27(8):1370-1378. DOI: 10.1038/s41591-021-01410-w PMID: 34108716

25. Accorsi EK, Britton A, Fleming-Dutra KE, Smith ZR, Shang N, Derado G, et al. Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants. JAMA. 2022;327(7):639-651. DOI: 10.1001/jama.2022.0470 PMID: 35060999

26. Vassallo M, Clement N, Lotte L, Manni S, Sindt A, Bertrand PM, et al. Prevalence and Main Clinical Characteristics of Fully Vaccinated Patients Admitted to Hospital for Delta Variant COVID-19. Front Med (Lausanne). 2022;9:809154.

DOI: 10.3389/fmed.2022.809154 PMID: 35308544

27. AlRuthia Y, Al-Salloum HF, Almohammed OA, Alqahtani AS, Al-Abdulkarim HA, Alsofayan YM, et al. Demographic Characteristics and Status of Vaccinated Individuals with a History of COVID-19 Infection Pre- or Post-Vaccination: A Descriptive Study of a Nationally Representative Sample in Saudi Arabia. Vaccines (Basel). 2022;10(2):323.

DOI: 10.3390/vaccines10020323 PMID: 35214781

28. Alimohamadi Y, Tola HH, Abbasi-Ghahramanloo A, Janani M, Sepandi M. Case fatality rate of COVID-19: a systematic review and meta-analysis. J Prev Med Hyg. 2021;62(2):E311-E320.

DOI: 10.15167/2421-4248/jpmh2021.62.2.1627 PMID: 34604571

29. Berenguer J, Ryan P, Rodríguez-Baño J, Jarrín I, Carratalà J, Pachón J, et al. Characteristics and predictors of death among 4035 consecutively hospitalized patients with COVID-19 in Spain. Clin Microbiol Infect. 2020;26(11):1525-1536.

DOI: 10.1016/j.cmi.2020.07.024 PMID: 32758659

30. Lin DY, Gu Y, Wheeler B, Young H, Holloway S, Sunny SK, et al. Effectiveness of Covid-19 Vaccines over a 9-Month Period in North Carolina. N Engl J Med. 2022;386(10):933-941.

DOI: 10.1056/NEJMoa2117128 PMID: 35020982

31. Zhang XB, Yang SJ, Lin Y, Chen LL, Zhuang YL, Zeng HQ. Clinical Characteristics of COVID-19 Patients' Postvaccination. Viral Immunol. 2022;35(3):236-243.

DOI: 10.1089/vim.2021.0204 PMID: 35333629